In Brief: FDA Fights for Access; ARI Idled; ICH, PIC/S and EU Launch Initiatives
This article was originally published in The Gold Sheet
Executive Summary
What happens now when plants block FDA inspections; how ARI drug shortage collaboration is falling short; how ICH is reforming; what PIC/S deems a deficiency; and how EU is updating the role of the QP.
You may also be interested in...
Pharma Gets More Time to Control Elemental Impurities
Delays in application of new USP and ICH limits on lead, mercury and other elemental impurities give industry more time to do the risk analysis and prepare to use new ICP-AES and ICP-MS test methods. The old heavy metals method was fine for yesterday’s lead-tainted water supply issues; the new methods are better for today’s global supply chain concerns.
ICH Enhances Regulators’ Roles While Preserving Industry Access
The International Conference on Harmonization strengthens the hand of regulatory authorities in consensus-based discussions with industry, while applauding the growing role of non-ICH authorities in its expert working groups.
As ICH Q3D Metal Impurity Limits Near, Industry Worries What New Tests May Find
With ICH planning to propose Q3D metal impurity limits in June and USP requiring new metals test methods soon thereafter, pharmaceutical companies are wondering whether any of their ingredients might fail the tests, perhaps requiring them to reformulate products or suspend production. Early indications from FDA and industry testing are largely reassuring, while highlighting some areas for further inquiry.